Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 19, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement...
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
August 18, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 07:00 ET
|
Kala Pharmaceuticals, Inc.
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and...
Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call
August 08, 2022 09:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August
August 04, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 22, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...
Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc
July 11, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 17, 2022 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., June 17, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
May 23, 2022 00:01 ET
|
Kala Pharmaceuticals, Inc.
--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease...